{"entity":{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","aka":[],"tldr":"A phase 1/2 trial of 177Lu-NYM032 injection in prostate cancer, run by Norroy Bioscience Co., LTD, active and no longer recruiting.","summary":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC is a phase 1/2 interventional study registered as NCT06383052 by Norroy Bioscience Co., LTD, with 30 participants enrolled, started 2024-04-26 and due to reach its primary completion in 2025-06-30. Interventions recorded: 177Lu-NYM032 injection.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06383052","url":"https://clinicaltrials.gov/study/NCT06383052"}],"tags":["pipeline","ctgov-ingest"],"related":["lu-177"],"indications":["prostate","prostate-mcrpc"],"sections":[],"technologies":[],"targets":["psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06383052","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","sponsor":"Norroy Bioscience Co., LTD","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06383052/","neighbours":{"isotope":[{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"indication":[{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}]}}